• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
A survey of 434 clinical trials about coronavirus disease 2019 in China.一项关于中国2019年冠状病毒病的434项临床试验的调查。
J Med Virol. 2020 Oct;92(10):1715-1717. doi: 10.1002/jmv.25779. Epub 2020 Mar 27.
2
Current State of Research About Chinese Herbal Medicines (CHM) for the Treatment of Coronavirus Disease 2019 (COVID-19): A Scoping Review.关于中药（CHM）治疗 2019 年冠状病毒病（COVID-19）的研究现状：范围综述。
J Altern Complement Med. 2020 Jul;26(7):557-570. doi: 10.1089/acm.2020.0189. Epub 2020 Jun 24.
3
Calling for improved quality in the registration of traditional Chinese medicine during the public health emergency: a survey of trial registries for COVID-19, H1N1, and SARS.呼吁提高公共卫生应急期间中医药注册质量：对 COVID-19、H1N1 和 SARS 临床试验注册的调查。
Trials. 2021 Mar 5;22(1):188. doi: 10.1186/s13063-021-05113-y.
4
Analysis of Chinese Herbal Formulae Recommended for COVID-19 in Different Schemes in China: A Data Mining Approach.分析中国不同方案中推荐用于 COVID-19 的中草药配方：一种数据挖掘方法。
Comb Chem High Throughput Screen. 2021;24(7):957-967. doi: 10.2174/1386207323666201001114101.
5
[Analysis on clinical study protocols of traditional Chinese medicine for coronavirus disease 2019].[2019年冠状病毒病的中医临床研究方案分析]
Zhongguo Zhong Yao Za Zhi. 2020 Mar;45(6):1232-1241. doi: 10.19540/j.cnki.cjcmm.20200220.501.
6
The therapeutic effects of traditional chinese medicine on COVID-19: a narrative review.中医药治疗 COVID-19 的疗效：叙述性综述。
Int J Clin Pharm. 2021 Feb;43(1):35-45. doi: 10.1007/s11096-020-01153-7. Epub 2020 Sep 24.
7
Clinical features and the traditional Chinese medicine therapeutic characteristics of 293 COVID-19 inpatient cases.293 例新冠肺炎住院患者的临床特征及中医治疗特点。
Front Med. 2020 Dec;14(6):760-775. doi: 10.1007/s11684-020-0803-8. Epub 2020 Sep 14.
8
An evidence mapping and analysis of registered COVID-19 clinical trials in China.中国注册 COVID-19 临床试验的证据图谱和分析。
BMC Med. 2020 Jun 1;18(1):167. doi: 10.1186/s12916-020-01612-y.
9
Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry.中国临床试验注册中心的 COVID-19 临床试验概况。
Emerg Microbes Infect. 2020 Dec;9(1):1695-1701. doi: 10.1080/22221751.2020.1791736.
10
Traditional Chinese Medicine treatment of COVID-19.中医药治疗 COVID-19。
Complement Ther Clin Pract. 2020 May;39:101165. doi: 10.1016/j.ctcp.2020.101165. Epub 2020 Apr 1.

引用本文的文献

1
Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment.间充质干细胞：COVID-19 治疗拼图中的新一块。
Front Immunol. 2020 Jul 3;11:1563. doi: 10.3389/fimmu.2020.01563. eCollection 2020.
2
Stem Cell-Based Therapy for Coronavirus Disease 2019.基于干细胞的 2019 冠状病毒病治疗。
Stem Cells Dev. 2020 Jun 1;29(11):679-681. doi: 10.1089/scd.2020.0071. Epub 2020 Apr 17.

本文引用的文献

1
Transplantation of ACE2 Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia.血管紧张素转换酶2间充质干细胞移植改善新型冠状病毒肺炎患者的预后。
Aging Dis. 2020 Mar 9;11(2):216-228. doi: 10.14336/AD.2020.0228. eCollection 2020 Apr.
2
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
3
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.新冠病毒的基因组特征和流行病学：对病毒起源和受体结合的影响。
Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.
4
First Case of 2019 Novel Coronavirus in the United States.美国首例 2019 新型冠状病毒病例。
N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.
5
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
6
A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment.一种在中国出现的新型冠状病毒——影响评估的关键问题
N Engl J Med. 2020 Feb 20;382(8):692-694. doi: 10.1056/NEJMp2000929. Epub 2020 Jan 24.
7
SPIRIT 2013 statement: defining standard protocol items for clinical trials.SPIRIT 2013 声明：定义临床试验的标准议定书项目。
Ann Intern Med. 2013 Feb 5;158(3):200-7. doi: 10.7326/0003-4819-158-3-201302050-00583.

A survey of 434 clinical trials about coronavirus disease 2019 in China.

作者信息

Leng Zikuan, Yin Dongfei, Zhao Zhe, Yan Miaoheng, Yang Yanlei, He Xijing, Zhao Robert Chunhua, Liu Hongjian

机构信息

Department of Orthopaedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

J Med Virol. 2020 Oct;92(10):1715-1717. doi: 10.1002/jmv.25779. Epub 2020 Mar 27.

DOI:10.1002/jmv.25779
PMID:32220077
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7228410/
Abstract
摘要